RTM for Pain Management: Beyond the Office Visit

Chronic pain is managed between office visits far more than it is managed during them. A pain management patient who sees their provider once a month is making functional decisions about their pain every single day — how much to move, when to take medication, whether a new activity is worth the expected flare. The provider who manages that patient only has clinical insight into how those decisions are going once every 30 days, at a snapshot appointment that may or may not reflect the patient’s actual between-visit experience. Remote Therapeutic Monitoring changes this. For the first time, pain management practices have a reimbursed clinical framework for monitoring what is happening to their patients between visits — and the revenue that comes with it.

Why Pain Management Is a Strong RTM Candidate

Pain management practices treat a patient population that is almost entirely defined by conditions that qualify for RTM. Musculoskeletal pain — chronic low back pain, cervical pain, joint pain, myofascial pain — is the primary diagnosis category for most pain management panels, and it maps directly to CPT 98977 (musculoskeletal RTM device supply). The conditions are chronic, the therapeutic management involves ongoing monitoring of pain response and functional status, and the between-visit period is clinically significant in a way that justifies structured remote oversight.

Pain management also has a specific clinical advantage in RTM: the monitoring data has direct impact on treatment decisions. A patient whose pain scores are trending upward two weeks after a spinal injection provides early data that informs whether the injection was effective, whether dose adjustment is needed, or whether escalation to the next treatment level is appropriate — information that in a traditional model the provider would not have until the next appointment.

The controlled substance management dimension of pain management adds a second RTM value layer. Medication adherence monitoring — patients logging their medication taking, reporting side effects, and flagging medication concerns — gives the prescribing provider real-time data that supports more informed prescribing decisions and provides documented evidence of between-visit oversight that is increasingly important in controlled substance management.

Conditions That Qualify

The diagnostic eligibility for pain management RTM is broad within the musculoskeletal category. Qualifying conditions include chronic low back pain with or without radiculopathy, cervical pain and cervicogenic headache, degenerative joint disease (hip, knee, shoulder, spine), myofascial pain syndrome, fibromyalgia, post-procedural pain management following spinal injections or nerve blocks, complex regional pain syndrome, and chronic pain associated with musculoskeletal injury.

For practices managing headache and migraine, the musculoskeletal RTM framework can apply to cervicogenic headache with a musculoskeletal component. Practices that manage neuropathic pain may find that some patients qualify under musculoskeletal RTM if their primary diagnosis has a musculoskeletal component, while others may require a different approach depending on the primary diagnosis coding.

The diagnosis must be supported in the medical record. Billing RTM for a musculoskeletal condition requires that the condition is documented as an active diagnosis under current treatment. This is typically not a documentation gap for established pain management patients, whose primary musculoskeletal conditions are almost always prominently documented in the chart.

The Monitoring Program Structure

A pain management RTM program typically monitors three categories of patient-reported data: pain intensity (using validated scales such as the Numeric Rating Scale or Brief Pain Inventory), functional status and activity levels, and medication adherence and side effect reporting. Some practices add sleep quality tracking, psychological well-being measures, or condition-specific functional questionnaires.

The monitoring cadence should be configured to match the clinical rhythm of the practice. Daily pain score logging with weekly functional status surveys is a common structure for chronic pain patients. Post-procedure patients — those who have just received an injection or block — may need more frequent monitoring in the first two weeks after the procedure and less frequent monitoring thereafter. The monitoring plan should be individualized in the documentation, not generic.

Medication adherence monitoring for pain patients requires care in how the monitoring is framed and documented. The purpose is clinical oversight, not surveillance, and the patient consent and monitoring plan should reflect this clearly. Documenting that medication adherence monitoring is part of an active therapeutic management program — not a compliance or diversion-detection program — is important for both patient engagement and audit defensibility.

Revenue Per Patient Math

The revenue potential of pain management RTM becomes clear when you run the per-patient math. A patient enrolled in RTM who has Medicare as their primary payer generates approximately $45 to $55 in 98977 device supply reimbursement per month, plus $55 to $75 in 98980 treatment management reimbursement. That is $100 to $130 per patient per month for the baseline two-code billing. A month where the patient requires more than 20 minutes of treatment management time adds another $45 to $55 in 98981 billing.

For a pain management practice with 150 chronic pain patients on Medicare, enrolling even 40% of that panel in RTM generates 60 enrolled patients. At $115 per patient per month as a conservative average, that is $6,900 in monthly RTM revenue — $82,800 annually — from a patient population the practice is already seeing. The incremental clinical staff time required to support 60 RTM patients is typically 15 to 20 hours per month, which at fully-loaded staff cost is approximately $400 to $500 in labor. The margin on a well-run RTM program at this scale is strong.

Documentation Essentials

Pain management RTM documentation must establish that a qualifying musculoskeletal condition is under active management, that the patient was enrolled in RTM with informed consent, that a monitoring device or software was supplied, that data was collected for at least 16 days in the billing period, and that clinical staff spent at least 20 minutes reviewing data and managing the patient’s care based on that data.

Pain management practices should be especially attentive to the data review documentation because the monitoring data in pain management is often clinically consequential. A note that reflects the practitioner or staff actually reviewed pain trends, made a clinical interpretation, and took or recommended action is more defensible — and more clinically valuable — than a generic note confirming data was received.

Enrolling Chronic Pain Patients

Chronic pain patients are often highly motivated RTM participants because the monitoring gives them a sense of agency over their condition and a channel for communicating with their care team between visits. The enrollment conversation should lead with clinical value: “We want to be able to track your pain and function between appointments so we can catch changes early and adjust your treatment plan sooner.” This framing resonates with patients who feel their pain is not adequately managed at the current visit frequency.

Practices that make the monitoring technology simple and the check-in process brief achieve higher enrollment retention. A pain patient who logs a 30-second pain score every morning is far more likely to maintain the 16-day threshold than one who is expected to complete a lengthy questionnaire. Start with the minimum viable monitoring dataset and expand based on patient engagement rather than starting with an ambitious monitoring program that patients find burdensome and stop using.

Post-Procedure Monitoring: A High-Value Application

Post-procedure monitoring is one of the highest-value RTM applications in pain management because the clinical need is acute, the monitoring period is time-bounded, and the data has direct clinical utility. A patient who has just received a spinal injection or nerve block is in a period of active clinical assessment: is the procedure working? Is the pain response following the expected trajectory? Are there early signs of complications or unexpected side effects?

In a traditional outpatient model, these questions are answered at the two-week or four-week post-procedure follow-up appointment. RTM answers them continuously. Daily pain scores in the first two weeks after a procedure provide a trajectory that the treating provider can evaluate without waiting for the follow-up visit. A patient whose pain scores are dropping steadily after an injection is on expected trajectory. A patient whose pain scores are unchanged or worsening after 10 days may need an earlier follow-up, a different approach, or clinical communication before the scheduled visit.

Post-procedure RTM monitoring is also time-limited in a way that makes the enrollment conversation easier. Many patients who might hesitate to commit to an ongoing monitoring program are comfortable with a 30 to 60 day post-procedure monitoring window. The enrollment is framed as temporary — “while you’re recovering from the injection, we want to track your progress closely” — which reduces the friction around the monitoring commitment. Practices that use this framing for post-procedure patients often find that patients who initially enrolled for a finite monitoring period choose to continue monitoring on an ongoing basis once they experience the benefit.

Integrating RTM with the Pain Management Visit

Pain management RTM is most clinically valuable when the monitoring data is incorporated into the in-office visit rather than managed as a separate administrative function. When a provider reviews a patient’s 30-day pain score trend before entering the exam room, the visit starts from a position of informed context rather than patient self-report recall. The provider already knows whether the past month has been better, worse, or similar to the prior period. The visit can focus on clinical decision-making rather than on establishing the clinical picture.

This integration requires that the RTM monitoring data be accessible in or alongside the EHR at the point of care — not in a separate system that providers have to log into independently. The practices with the highest provider adoption of RTM data review are those where the monitoring trend is presented automatically in the pre-visit summary, not those where the provider has to take an additional step to access it.

Controlled Substance Management and RTM Documentation

Pain management practices that prescribe controlled substances have an additional documentation benefit from RTM beyond the billing revenue. Medication adherence monitoring data — patient-reported medication taking, side effect reports, and any divergence from the prescribed regimen — creates a documented record of between-visit oversight that supports the practice’s controlled substance management policies.

As scrutiny of opioid and controlled substance prescribing has increased, practices benefit from documented evidence that they are actively monitoring patient response to and adherence with controlled medications between office visits. RTM monitoring data that shows a patient is reporting consistent, appropriate use — or that flags anomalies for clinical follow-up — is a record of clinical oversight that a traditional visit-only practice cannot produce.

This documentation value is separate from the RTM billing value but compounds it. A practice that uses RTM for post-procedure monitoring of pain response and medication adherence is simultaneously generating billable RTM revenue, improving clinical decision-making, and building a documented record of ongoing patient oversight that supports its controlled substance management program. The same investment serves three distinct practice needs.